Skip to main content
Clinical Trials/DRKS00025993
DRKS00025993
Not yet recruiting
Not Applicable

Observational study to evaluate acceptability and bleeding profile with Drospirenone 4 mg, in a regimen of use 24/4 in contraception (Slinda®, Exeltis HealthCare) after six months of use. - EXELINDA

Exeltis Healthcare0 sites300 target enrollmentAugust 6, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Z30
Sponsor
Exeltis Healthcare
Enrollment
300
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 6, 2021
End Date
TBD
Last Updated
last year
Study Type
Observational
Sex
Female

Investigators

Sponsor
Exeltis Healthcare

Eligibility Criteria

Inclusion Criteria

  • 1\.Women over 18 years up to 50 years.
  • 2\. They use Slinda ® for the approved indication (contraception) and have started treatment at least 6 months before the visit.
  • 3\. They shall give informed consent in order to participate in the study.

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials